Vir Biotechnology (NASDAQ: VIR) officer plans 14,352-share sale after 25K sale

Rhea-AI Filing Summary

Vir Biotechnology, Inc. (VIR) is the issuer for a planned sale of common stock by former officer Jason V. O'Byrne under Rule 144. The notice lists up to 14,352 shares of common stock to be sold, with an aggregate market value of $142,124.00, following a stock option exercise for cash on 08/24/2026. The securities are held at Fidelity Brokerage Services LLC and are listed on NASDAQ. The notice also reports that O'Byrne sold 25,000 shares of Vir common stock during the past three months for proceeds of $245,297.50.

Key Figures

Shares to be sold: 14,352 shares Aggregate market value of proposed sale: $142,124.00 Shares outstanding referenced: 169,215,958 shares +3 more

6 metrics

Shares to be sold 14,352 shares Common stock proposed to be sold by Jason V. O'Byrne under Rule 144

Aggregate market value of proposed sale $142,124.00 Value of 14,352 Vir Biotechnology common shares listed in the Form 144

Shares outstanding referenced 169,215,958 shares Vir Biotechnology common shares referenced in the securities information section

Shares sold in past 3 months 25,000 shares Vir Biotechnology common shares sold on 08/21/2026

Proceeds from past 3-month sale $245,297.50 Total proceeds from 25,000 Vir Biotechnology shares sold on 08/21/2026

Option exercise date 08/24/2026 Date of stock option exercise related to the 14,352 shares

Key Terms

Rule 144, Stock Option Exercise, attorney-in-fact

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Stock Option Exercise financial

"Common | 08/24/2026 | Stock Option Exercise | Issuer"

A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.

attorney-in-fact regulatory

"as attorney-in-fact for Jason V. O'Byrne"

An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

FAQ

What insider sale is disclosed for Vir Biotechnology, Inc. (VIR) in this Form 144?

The notice reports that former officer Jason V. O'Byrne intends to sell up to 14,352 shares of Vir Biotechnology common stock under Rule 144. These shares are associated with a stock option exercise for cash dated 08/24/2026 and are held at Fidelity Brokerage Services LLC.

What is the aggregate market value of the Vir (VIR) shares proposed for sale?

The Form 144 lists an aggregate market value of approximately $142,124.00 for the 14,352 shares of Vir Biotechnology common stock proposed to be sold. The shares are listed on NASDAQ and held at Fidelity Brokerage Services LLC.

How many Vir (VIR) shares did Jason V. O'Byrne sell in the past three months?

During the past three months, Jason V. O'Byrne sold 25,000 shares of Vir Biotechnology common stock. The notice reports total proceeds of approximately $245,297.50 from this prior sale, dated 08/21/2026.

What is the nature of the Vir (VIR) shares being sold under this Form 144?

The securities are common stock of Vir Biotechnology, Inc. The Form 144 states that the 14,352 shares to be sold relate to a Stock Option Exercise with the issuer, with the option exercise dated 08/24/2026 and settled in cash.

What share count for Vir Biotechnology (VIR) is referenced in this Form 144?

The Form 144 references 169,215,958 shares of Vir Biotechnology common stock. This figure appears in the securities information section in connection with the issuer’s common stock and provides a share-count context for the transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/24/2026 - 05:11 PM Accepted by SEC EDGAR 08/24/2026 - 05:11 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001871145
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Vir Biotechnology, Inc.
SEC File Number	001-39083
Address of Issuer	1800 OWENS STREET SUITE 900 SAN FRANCISCO CALIFORNIA 94158
Phone	415-906-4324
Name of Person for Whose Account the Securities are To Be Sold	O'Byrne Jason
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Former Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	14352	142124.00	169215958	08/24/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/24/2026	Stock Option Exercise	Issuer			14352	08/24/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Jason V. O'Byrne 1800 Owens Street Suite 900 San Francisco CA 94158	Common	08/21/2026	25000	245297.50

144: Remarks and Signature

Remarks
Date of Notice	08/24/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Adam Gehring, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Jason V. O'Byrne
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)